ClinicalTrials.gg
RecruitingNCT07471659PostWelLBUpdated Sep 2, 2026

Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels

An interventional study of Humiome Post LB and Microcrystalline Cellulose in Stress, sponsored by dsm-firmenich Switzerland AG. Recruiting at 1 site in France. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Study summary

The placebo-controlled, double blind parallel intervention trial "PostWelLB" aims to test whether 3 months of daily supplementation with the postbiotic product "Humiome® Post LB" (HPLB; 340 mg / day) can reduce self-reported stress (PSS10 questionnaire)- in an older (50 - 75 years; all genders) population in France.

Read the detailed description

The clinical study "PostWelLB" aims to test whether 3 months of daily supplementation with the postbiotic product "Humiome® Post LB" (HPLB) can reduce stress in an older population compared with placebo.

The investigational product (IP) HPLB is a postbiotic according to the International Scientific Association of Probiotics and Prebiotics (ISAPP), who defined postbiotics as "preparations of inanimate micro-organisms or components thereof that provide a health benefit on the host". In essence, HPLB is a fermentation product containing heat inactivated bacterial bodies of Limosilactobacillus fermentum (CNCM I-2998) and Lactobacillus delbrueckii (CNCM I-4831) and metabolite-rich spent fermentation medium (mainly lactic acid). The product also contains lactose, which is used as drying support.

HPLB was developed from an over-the-counter drug, Lactéol, which has been used for decades in more than 30 countries in support of oral rehydration in acute diarrhoea and to improve digestive comfort. Lactéol has an extensive safety record and has been studied in several clinical trials in which it has been shown to reduce digestive upset, improve abdominal comfort, reduce occasional bloating, and help achieve or maintain normal bowel movements.

In addition to effects on digestive health, recent preclinical studies on mice and dogs suggested that HPLB can also affect mood and stress, in line with the emerging concept that the intestinal microbiome may affect wellbeing.

In the present placebo-controlled, double blind clinical trial, the investigators therefore wish to test if daily supplementation with HPLB can reduce stress and improve wellbeing. This will be tested in older volunteers, because the risk of stress increases with age. Verum or placebo will each be administered daily for 12 weeks in capsules made from plant-based material which each also contain small amounts of a widely used flowing agent (magnesium stearate).

Additional endpoints of the trial relate to sleep quality, digestive health, and faecal microbiome composition.

02

Conditions studied

  • Stress

Keywords

  • stress
  • wellbeing
  • healthy aging
  • postbiotic
  • microbiome
03

In context

Lead sponsor

dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged between 50 and 75 years old (limits included),
  • (BMI) ≥ 18.5 and \< 30 kg/m²
  • Presenting a level of psychological stress characterized by a PSS-10 score ≥ 14 and ≤ 26,
  • For women: not at risk of pregnancy (as per definitions of Appendix 13) Participants currently of , using an effective method of .
  • Menopausal without hormone replacement therapy (estrogenic replacement therapy stopped since more than 3 months can be included)
  • Good general and mental health according to the opinion of the investigator: No relevant abnormalities from medical history nor from the medical consultation
  • Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits)
  • Able and willing to participate to the trial by complying with the protocol procedures as evidenced by a dated and signed ICF
  • Affiliated with a social security scheme,
  • With access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available emergency health services,
  • Agreeing to be registered in the national database of subjects participating in clinical research,
  • Having a smartphone or personal computer compatible with the eConsult and ePRO applications.

Exclusion criteria

EXCLUSION CRITERIA:

  • Suffering from a metabolic disorder such as treated or untreated diabetes,
  • Suffering from thyroid dysfunction, high blood pressure or other metabolic disorders treated for less than 6 months and/or non-stabilized,
  • Suffering from a severe chronic disease: cancer, , renal failure, hepatic or biliary disorders ongoing (except for cholecystectomy since more than two years and asymptomatic), chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble (except for mild asthma under treatment),
  • Suffering from GI disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease, Chron's disease, etc.),
  • With a known food allergy or intolerance or to any of the trial products' ingredients,
  • Women who are pregnant or lactating or intend on becoming pregnant within the following six months,
  • Having a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disturbance, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other psychiatric/neurologic condition that could interfere with the interpretation of the study results in the opinion of the investigator,
  • Having recently experienced or currently experiencing a significant stress as per investigator's judgment (e.g. grieving, divorce, moving, etc.),
  • Having a condition and/or receiving a treatment that may cause (e.g.: under immunomodulating treatment for HIV infection, allograft, auto-immune disease or cancer, etc.)
  • Under treatment or dietary supplement which could significantly affect parameter(s) followed during the trial according to the investigator or stopped less than one month prior to V1,
  • Under treatment with one or more of the following treatments stopped less than one month prior to V1:
  • psychotropic medications (including antidepressants and tranquilizers), stimulant medications, and/or narcotics having an effect on stress, sleep aid medications, supplements, and/or products, including antihistamines, acid-blocking medication (e.g., proton pump inhibitor, H2 blocker),
  • Under treatment with an effect on the microbiome such as antibiotics stopped less than one month prior to V1,
  • Having a lifestyle deemed incompatible with the trial according to the Investigator as described below:
  • Practicing a high-level of physical activity (defined as more than 10 hours of intense physical activity a week, walking excluded),
  • Regularly consuming more than 2 standard drinks of alcohol daily or 14 weekly or not agreeing to keep alcohol consumption habits unchanged throughout the study,
  • With a significant change in dietary or physical activity habits in the 3 months prior to randomisation (no hyper or hypocaloric diet, no high-protein diet, no prolonged fasting for more than one week, no planned change in the level of sports activity in the next 3 months),
  • With a personal history of anorexia nervosa, bulimia, or significant eating disorders according to the Investigator,
  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
  • Having received, during the last 12 months, indemnities for clinical trial higher or equal to 6000 Euros,
  • Under legal protection (guardianship, wardship) or deprived of rights following an administrative or judicial decision,
  • Presenting a psychological or linguistic incapability to sign the ICF, Impossible to contact in case of emergency.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Active Treatment

    One-hundred participants will be randomized to the active treatment (verum) arm. Participants receive 2 capsules per day, taken simultaneously after breakfast, to provide a daily dose of 340 mg HPLB consistent with 10 billion heat-inactivated bacterial cell bodies. The opaque capsules are size 0 and produced from plant-based material (Hydroxy-Propyl Methyl Cellulose). Each capsule contains 2 mg Magnesium Stearate used as flowing agent for capsule filling.

    Dietary Supplement: Humiome Post LB

  • Placebo comparator
    Placebo

    One-hundred participants will be randomized to the control arm and will receive placebo. Participants receive 2 capsules per day, taken simultaneously after breakfast, to provide a daily dose of 340 mg microcrystalline cellulose. The opaque capsules are size 0 and produced from plant-based material (Hydroxy-Propyl Methyl Cellulose). Each capsule contains 2 mg Magnesium Stearate used as flowing agent for capsule filling.

    Other: Microcrystalline Cellulose

Interventions

  • Dietary supplementHumiome Post LB

    Humiome Post LB is a postbiotic preparation according to the 2021 ISAPP definition (PMID: 33948025). It contains heat-treated co-fermented Limosilactobacillus fermentum (CNCM I-4831) and Lactobacillus delbrueckii ssp. lactis (CNCM I-4831), dried together with heat-treated spent fermentation medium on lactose as carrier.

  • OtherMicrocrystalline Cellulose

    MCC is typically sourced from wood pulp, or it can be chemically synthesized. It consists of linear chains of glucose, which are interlinked with β1,4-glycosidic bonds and cannot be broken by digestive enzymes. It is a very poor substrate for gut micro-organisms and is thus a good material to serve as placebo.

    Also known as: MCC

06

What researchers measure

Primary outcomes

  1. The primary outcome measure is the Perceived Symtoms of Stress 10 (PSS10) questionnaire, which assesses perceived levels of stress

    The PSS-10 questionnaire is a validated tool to assess self-reported levels of stress. It was originally developed in 1988 by Cohen and Williamson and published in "The social psychology of health" (pp. 31-67). S. Spacapan \& S. Oskamp (Eds.), Newbury Park, CA: Sage.

    Time frame: PSS-10 will be assessed at baseline and at study end, 12 weeks later

Secondary outcomes

  1. Perceived stress (PSS-10) after 6 weeks

    Stress will also be assesed with the PSS-10 tool half-way through the intervention (6 weeks)

    Time frame: Week 6 of 12

  2. Sleep quality after 6 and 12 weeks, assessed with the SHI (Sleep Hygiene Index) questionnaire

    The SHI questionnaire is a likert-scale questionnaire developed in 2006 (Mastin, D. F., Bryson, J., \& Corwyn, R. (2006). Assessment of sleep hygiene using the Sleep Hygiene Index. Journal of Behavioral Medicine).

    Time frame: Baseline, week 6 and week 12 (study end)

  3. Digestive health after 6 and 12 weeks

    Digestive health will be assessed with the Gastrointestinal Symptom Rating Score questionnaire (GSRS). It is questionnaire with a 7-point Likert-scale (7 = most severe) with questions related to Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. It was developed by Svedlund et al. (Svedlund J, Sjödin I, Dotevall G. GSRS - A Clinical Rating Scale For Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome and Peptic Ulcer Disease. Digestive Diseases and Sciences 1988; 33:129-134)

    Time frame: Baseline, week 6 and week 12

  4. Depression, Anxiety and Stress

    These are assessed with the DASS-21 questionnaire. It uses a 4-point Likert scale for 21 questions with 7 questions each in the field of depression, anxiety, and stress. It was developed by Lovibond et al. Lovibond, S. H., \& Lovibond, P. F. (1995). Manual for the Depression Anxiety Stress Scales. Sydney: Psychology Foundation of Australia.

    Time frame: Baseline, 6 and 12 weeks.

  5. Stool frequencies

    Mean daily number of bowel movements during the last 3 days before each visit. Recorded in a diary by each participant.

    Time frame: Assessed at baseline, week 6, and week 12

  6. Stool consistency

    Stool consistency is recorded with the Bristol Stool Scale as aid. The 7 point visual scale was developed in the UK by Stephen Lewis and Ken Heaton. Lewis, Heaton (1997). "Stool form scale as a useful guide to intestinal transit time". Scand. J. Gastroenterol. 32 (9): 920-924. It will be recorded in a diary for three days before each visit.

    Time frame: Baseline, week 6, week 12

Other outcomes

  1. Gut Microbiome diversity and function after 6 and 12 weeks

    DNA from fecal samples will be shotgun-sequenced (Illumina Hiseq 150 x2) and taxonomic (alpha and beta-diversity) and functional composition assessed by aligning functional gene copy numbers with known database (Kegg). The gut metabolomic profile will be analysed using semi-polar LC-MS / MS methods to detect the abundance of metabolites known or hypothesized to be involved in stress such as GABA, serotonin or melatonin. The faecal organic acids (acetate, propionate, butyrate, valerate, lactate) will be analysed by a targeted quantitative SCFA method (GC-MS).

    Time frame: Baseline and weeks 6 and 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 13, 2026
StartActual
Jan 1, 2026
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07471659
Collaborators
BioFortis
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Jan 1, 2026
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Eleonora Rossi, PhD
Contact
eleonora.rossi@biofortis.fr
+33 240205799
Erik Eckhardt, PhD
Contact
erik.eckhardt@dsm-firmenich.com
+33 659328475
Erik Eckhardt, PhD
study director · dsm-firmenich Houdan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion